WO2018051297A3 - Non—saponifiable compounds of natural lipids for use in the treatment of infective pahologies and peripheral neuropathies - Google Patents

Non—saponifiable compounds of natural lipids for use in the treatment of infective pahologies and peripheral neuropathies Download PDF

Info

Publication number
WO2018051297A3
WO2018051297A3 PCT/IB2017/055625 IB2017055625W WO2018051297A3 WO 2018051297 A3 WO2018051297 A3 WO 2018051297A3 IB 2017055625 W IB2017055625 W IB 2017055625W WO 2018051297 A3 WO2018051297 A3 WO 2018051297A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
infective
steroidal
pathology
imbalance
Prior art date
Application number
PCT/IB2017/055625
Other languages
French (fr)
Other versions
WO2018051297A2 (en
Inventor
Chiara De Gregorio
Original Assignee
Codex V Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codex V Srl filed Critical Codex V Srl
Publication of WO2018051297A2 publication Critical patent/WO2018051297A2/en
Publication of WO2018051297A3 publication Critical patent/WO2018051297A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates, in particular, to a pharmaceutical composition comprising the non-saponifiable moieties derived from a least one lipid of natural, vegetable and/or animal origin, for use in the treatment of those infective pathologies, such as AIDS and/or diabetic foot and/or diabetes and/or general systemic infections, even non-responding to other treatments of any origin (such as fungal, bacterial, viral) and/or septicaemia and/or exanthematous pathologies, chickenpox, zoster, measles, hand-foot-mouth diseases, contagious mollusc and/or hepatitis and/or pneumonias and/or renal infections and/or osteomyelitis and/or fistulizations, and/or necrotizing fascitis and/or condylomas and/or cystitis, which are caused by the permanent (or chronic) alteration (or imbalance) of the normal physiological equilibrium of the steroidal balance in an individual suffering from said pathology; and/or of those peripheral neuropathologies such as diabetic neuropathies and/or thalassaemia major and/or thrombocytopenia and/or algodystrophy and/or carpal tunnel, which are caused by permanent (or chronic) alteration (or imbalance) of the normal physiological equilibrium of the steroidal balance in an individual suffering from said pathology. Said pharmaceutical composition is particularly adapted for transdermal and/or transmucosal topical administration.
PCT/IB2017/055625 2016-09-19 2017-09-18 Non—saponifiable compounds of natural lipids for use in the treatment of infective pahologies and peripheral neuropathies WO2018051297A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000093768A IT201600093768A1 (en) 2016-09-19 2016-09-19 UNSAPONIFYABLE OF NATURAL LIPIDS FOR USE IN THE TREATMENT OF INFECTIOUS PATHOLOGIES AND PERIPHERAL NEUROPATHIES
IT102016000093768 2016-09-19

Publications (2)

Publication Number Publication Date
WO2018051297A2 WO2018051297A2 (en) 2018-03-22
WO2018051297A3 true WO2018051297A3 (en) 2018-04-26

Family

ID=57909886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/055625 WO2018051297A2 (en) 2016-09-19 2017-09-18 Non—saponifiable compounds of natural lipids for use in the treatment of infective pahologies and peripheral neuropathies

Country Status (2)

Country Link
IT (1) IT201600093768A1 (en)
WO (1) WO2018051297A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251953B1 (en) * 1992-10-30 2001-06-26 Andrew Brookner Beta-carotene therapy of individuals having abnormal immunological and serological indices, and individuals having infections and diseases causing changes therein
WO2004035059A1 (en) * 2002-10-16 2004-04-29 Alan Fergusson Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof
ZA201107798B (en) * 2010-10-25 2012-09-26 Cape Peninsula Univ Of Tech Micronutrient suppliment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251953B1 (en) * 1992-10-30 2001-06-26 Andrew Brookner Beta-carotene therapy of individuals having abnormal immunological and serological indices, and individuals having infections and diseases causing changes therein
WO2004035059A1 (en) * 2002-10-16 2004-04-29 Alan Fergusson Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof
ZA201107798B (en) * 2010-10-25 2012-09-26 Cape Peninsula Univ Of Tech Micronutrient suppliment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 201255, Derwent World Patents Index; AN 2012-P99459, XP002768721 *

Also Published As

Publication number Publication date
IT201600093768A1 (en) 2018-03-19
WO2018051297A2 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
EA201501032A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND ITS APPLICATIONS
BR112015024411A2 (en) macrocyclic desaza purinones for the treatment of viral infections
BR112014016810A2 (en) compositions and methods for treating metabolic disorders
MX2013003635A (en) N-heteroaryl compounds.
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
CO2017006898A2 (en) Insulin glargine / lixisenatide fixed ratio formulation
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
EA201300136A1 (en) DRUG AND METHOD OF PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
MX2017009929A (en) Compositions and methods for improved muscle metabolism.
WO2018051297A3 (en) Non—saponifiable compounds of natural lipids for use in the treatment of infective pahologies and peripheral neuropathies
TWD181994S (en) Junction for a vacuum circuit
EA201590752A1 (en) PYRAMIDINDION DERIVATIVES PREPARATIONS
EA201690395A1 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING BISOPROLOL AND RAMIPRIL
IN2013CH05288A (en)
WO2015066664A3 (en) Compositions and methods for administration of an enzyme to a subject's airway
CN105682672A8 (en) Containing the geranyl flavone from royal paulownia as effective ingredient for suppressing the compositions of neuraminidase activity
GB201204632D0 (en) Delivery system
BR112015013223A2 (en) pharmaceutical composition
Ripa Antineoplastics/antiretrovirals
EA201270717A2 (en) LYOPHYLIZED PREPARATION OF ATP AND THE COMPLEX OF VITAMINS GROUP B AND ATP AND THE COMPLEX OF VITAMINS GROUP IN THE FORM OF INJECTIONS
Hara Peginterferon-α-2b/ribavirin/telaprevir
BR112015003344A2 (en) pharmaceutical composition for increasing the content and availability of cyclic adenosine monophosphate in a body and preparing it
UA102844U (en) A TABLE CONTAINING DL-HYDROSPARAGINATE MAGNESIUM TETRAHYDRATE, POTASSIUM DL-ASPARAGINATE POTASSIUM AND DRY BLOOD-RED DRY EXTRACT
CN302267234S (en) Elevator call box (8mm ultra-thin)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17787255

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17787255

Country of ref document: EP

Kind code of ref document: A2